CN108373437A - 一种阿托伐他汀钙异构体的制备方法 - Google Patents
一种阿托伐他汀钙异构体的制备方法 Download PDFInfo
- Publication number
- CN108373437A CN108373437A CN201810305718.XA CN201810305718A CN108373437A CN 108373437 A CN108373437 A CN 108373437A CN 201810305718 A CN201810305718 A CN 201810305718A CN 108373437 A CN108373437 A CN 108373437A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- atorvastatin calcium
- preparation
- carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical class CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 101710150697 Inositol monophosphatase 1 Proteins 0.000 claims abstract description 11
- 101710150707 Inositol monophosphatase 2 Proteins 0.000 claims abstract description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 8
- -1 anilino- Chemical class 0.000 claims abstract description 6
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 60
- 150000001875 compounds Chemical class 0.000 claims description 47
- 238000006243 chemical reaction Methods 0.000 claims description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 229940126214 compound 3 Drugs 0.000 claims description 22
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 229940125782 compound 2 Drugs 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 229940125898 compound 5 Drugs 0.000 claims description 12
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 10
- 101710126181 Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 claims description 10
- 101710126176 Insulin-like growth factor 2 mRNA-binding protein 2 Proteins 0.000 claims description 10
- 102100029083 Minor histocompatibility antigen H13 Human genes 0.000 claims description 10
- 102100023501 Signal peptide peptidase-like 3 Human genes 0.000 claims description 10
- 101710111748 Signal peptide peptidase-like 3 Proteins 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 10
- 150000002148 esters Chemical group 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003208 petroleum Substances 0.000 claims description 10
- 239000003513 alkali Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 6
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 6
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 229960005147 calcium acetate Drugs 0.000 claims description 6
- 239000001639 calcium acetate Substances 0.000 claims description 6
- 235000011092 calcium acetate Nutrition 0.000 claims description 6
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 claims description 5
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 claims description 5
- 229940125904 compound 1 Drugs 0.000 claims description 5
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000007670 refining Methods 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 238000006000 Knoevenagel condensation reaction Methods 0.000 claims description 4
- 238000006086 Paal-Knorr synthesis reaction Methods 0.000 claims description 4
- 238000007296 Stetter synthesis reaction Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 4
- 238000006482 condensation reaction Methods 0.000 claims description 4
- 238000010931 ester hydrolysis Methods 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- 150000003557 thiazoles Chemical class 0.000 claims description 4
- 238000005191 phase separation Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 6
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000008025 crystallization Effects 0.000 claims 2
- 229960001770 atorvastatin calcium Drugs 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 239000013558 reference substance Substances 0.000 abstract description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- BURFOJRYLQGPSB-UHFFFAOYSA-L calcium;heptanoate Chemical compound [Ca+2].CCCCCCC([O-])=O.CCCCCCC([O-])=O BURFOJRYLQGPSB-UHFFFAOYSA-L 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 102100035679 Inositol monophosphatase 1 Human genes 0.000 abstract 1
- 102100021608 Inositol monophosphatase 2 Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XQKKWWCELHKGKB-UHFFFAOYSA-L calcium acetate monohydrate Chemical compound O.[Ca+2].CC([O-])=O.CC([O-])=O XQKKWWCELHKGKB-UHFFFAOYSA-L 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- BDQRQMLWZJQQKS-UHFFFAOYSA-M 2-(3-ethyl-4-methyl-1,3-thiazol-3-ium-5-yl)ethanol;bromide Chemical compound [Br-].CC[N+]1=CSC(CCO)=C1C BDQRQMLWZJQQKS-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940067460 calcium acetate monohydrate Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- FGQFDXSSZHUQQN-UHFFFAOYSA-N CC(C)C(C(C(C(c(cc1)ccc1F)=O)c1ccccc1)C(NC1=CC=CCC1)=O)=O Chemical compound CC(C)C(C(C(C(c(cc1)ccc1F)=O)c1ccccc1)C(NC1=CC=CCC1)=O)=O FGQFDXSSZHUQQN-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- SHZPNDRIDUBNMH-NIJVSVLQSA-L atorvastatin calcium trihydrate Chemical compound O.O.O.[Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 SHZPNDRIDUBNMH-NIJVSVLQSA-L 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012503 pharmacopoeial method Methods 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- HWSHVKNLMBMKSR-UHFFFAOYSA-N tert-butyl 2-[6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate Chemical compound CC(C)(C)OC(=O)CC1CC(CCN)OC(C)(C)O1 HWSHVKNLMBMKSR-UHFFFAOYSA-N 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
时间(min) | A相:水 | B相:甲醇 | 流速(mL/min) |
0 | 30% | 70% | 50 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810305718.XA CN108373437A (zh) | 2018-04-08 | 2018-04-08 | 一种阿托伐他汀钙异构体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810305718.XA CN108373437A (zh) | 2018-04-08 | 2018-04-08 | 一种阿托伐他汀钙异构体的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108373437A true CN108373437A (zh) | 2018-08-07 |
Family
ID=63032093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810305718.XA Pending CN108373437A (zh) | 2018-04-08 | 2018-04-08 | 一种阿托伐他汀钙异构体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108373437A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109336319A (zh) * | 2018-09-20 | 2019-02-15 | 河南慧锦药业有限公司 | 一种高浓度含苯胺废水和含苯甲醛废水的综合预处理方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101580479A (zh) * | 2008-05-14 | 2009-11-18 | 河南豫辰精细化工有限公司 | 一种降低阿托伐他汀中间体内杂质的方法 |
CN101805279A (zh) * | 2010-01-22 | 2010-08-18 | 绍兴民生医药有限公司 | 阿托伐他汀钙的制备方法 |
CN101929985A (zh) * | 2009-06-26 | 2010-12-29 | 北京德众万全药物技术开发有限公司 | 一种用高效液相色谱法测定阿托伐他汀钙有关物质的方法 |
CN104931599A (zh) * | 2015-04-15 | 2015-09-23 | 北京嘉林药业股份有限公司 | 一种阿托伐他汀钙有关物质的测定方法 |
-
2018
- 2018-04-08 CN CN201810305718.XA patent/CN108373437A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101580479A (zh) * | 2008-05-14 | 2009-11-18 | 河南豫辰精细化工有限公司 | 一种降低阿托伐他汀中间体内杂质的方法 |
CN101929985A (zh) * | 2009-06-26 | 2010-12-29 | 北京德众万全药物技术开发有限公司 | 一种用高效液相色谱法测定阿托伐他汀钙有关物质的方法 |
CN101805279A (zh) * | 2010-01-22 | 2010-08-18 | 绍兴民生医药有限公司 | 阿托伐他汀钙的制备方法 |
CN104931599A (zh) * | 2015-04-15 | 2015-09-23 | 北京嘉林药业股份有限公司 | 一种阿托伐他汀钙有关物质的测定方法 |
Non-Patent Citations (1)
Title |
---|
NAIDU A. A.ET AL: "Synthesis of novel impurities in 2-(2-(4-fluorophenyl)-2-oxo-1- phenylethyl)-4-methyl-3-oxo-N-phenylpentanamide; an atorvastatin intermediate", 《ORG. COMMUN.》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109336319A (zh) * | 2018-09-20 | 2019-02-15 | 河南慧锦药业有限公司 | 一种高浓度含苯胺废水和含苯甲醛废水的综合预处理方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111201212B (zh) | 一种非罗考昔及其中间体的合成方法 | |
JPS582936B2 (ja) | 5↓−アロイルピロ−ル酢酸およびその塩類の製法 | |
US8884046B2 (en) | Compounds useful in the synthesis of benzamide compounds | |
CN102516122B (zh) | 制备邻羟基苯甲腈的dmf溶液的方法 | |
WO2015104721A2 (en) | An improved process for the preparation of tranexamic acid | |
CN108373437A (zh) | 一种阿托伐他汀钙异构体的制备方法 | |
WO2017060885A1 (en) | An improved process for preparation of atorvastatin or pharmaceutically acceptable salts thereof | |
JP2019108351A (ja) | モリンドン及びその塩の製造方法 | |
US20080076825A1 (en) | Novel Crystalline Forms of Entacapone and Production Thereof | |
US20060199855A1 (en) | Process for producing atorvastatin hemicalcium | |
JP6484567B2 (ja) | 2−アミノ−1,3−プロパンジオール化合物およびその塩の製造のための方法 | |
CH619935A5 (zh) | ||
JPH1087633A (ja) | キラルなコハク酸誘導体の製造方法 | |
US5892055A (en) | Preparation of mibefradil via an acetamide anion | |
EP2665700A2 (en) | One-pot preparation of cyclobenzaprine hydrochloride | |
WO2007086076A2 (en) | An improved process for preparation of leflunomide | |
US6031114A (en) | Process for pyrrolidinyl hydroxamic acid compounds | |
US20190314385A1 (en) | Process for Preparation of Chlorpromazine or its Pharmaceutically Acceptable Salts | |
CN108203396B (zh) | 一种脑啡肽酶抑制剂的合成 | |
HU203716B (en) | Process for producing optically active amino-acids | |
CA2930089C (en) | Fingolimod hydrochloride process | |
ITMI971006A1 (it) | Processo per la preparazione del 4-(6'-metossi-2'-naftil)butan-2-one [nabumetone] | |
JP3684332B2 (ja) | エナンチオ選択的合成 | |
EP2448916B1 (en) | Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivatives | |
JP5960243B2 (ja) | 2工程での3,5−ジオキソヘキサン酸エステルの製造 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 225321 No. 8, Tai Zhen Road, Taizhou medical hi tech Zone, Jiangsu Applicant after: JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO., LTD. OF YANGTZE RIVER PHARMACEUTICAL Group Applicant after: YANGTZE RIVER PHARMACEUTICAL GROUP Co.,Ltd. Address before: 225321 No. 8 Tai Zhen Road, Binjiang Industrial Park, Taizhou Economic Development Zone, Taizhou, Jiangsu. Applicant before: Jiangsu Haici Biological Pharmaceutical Co., Ltd. of Yangtze River Pharmaceutical Group Applicant before: YANGTZE RIVER PHARMACEUTICAL GROUP Co.,Ltd. |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180807 |